Polymeropoulos Mihael Hristos's Form 4 filing
Vanda Pharmaceuticals Inc. (VNDA) · filed May 21, 2025
- Accession no.
- 0000950170-25-076012
- Filed
- May 21, 2025
- Trade date
- May 21, 2025
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market purchases total $44.0K. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Polymeropoulos Mihael HristosCIK 0001355537 | Director, Officer (President and CEO), Other: Chairman of the Board |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 21, 2025 | Common Stock | PPurchaseAcquired | +9,519 | $4.40 | +$41,883.6 | 2,325,250 | Direct | |
| May 21, 2025 | Common Stock | PPurchaseAcquired | +481 | $4.39 | +$2,111.59 | 2,325,731 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.